Clinical Trial

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-15.
Trial Details
NCT Number NCT06512207
Lead Sponsor Jinzhou Medical University
Collaborators: The First Affiliated Hospital of Zhengzhou University
Conditions NSCLC, Stage III, NSCLC, Stage IV
Enrollment 80 participants
Start Date 2023-12-03
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-09